Recruiting

Genomic Registry

Sponsor:

BostonGene

Code:

NCT04991922

Conditions

Malignancy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The purpose of this project is to develop a comprehensive database of genomic, transcriptomic, molecular, and clinical characteristics of oncology patients to discover, define, and develop genomic and transcriptomic markers to improve future clinical outcomes across cancer types

Conditions

Malignancy

Study ID

NCT04991922

Start date

Jul 1, 2021

Status verified date

Feb, 2024

Completion date

Jul 1, 2036

Anticipated

Primary completion date

Jul 1, 2031

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Suspected or confirmed malignancy
2. Planned comprehensive genomic (> 100 genes) and/or molecular analysis; or genomic and/or molecular data available from prior sequencing
3. Baseline demographics and treatment information available
4. Willingness for future contact by BIRG study personnel to provide information regarding associated cancer outcomes and treatment.
5. Signed informed consent to participate in the study.
6. Living in the United States at the time of enrollment

Exclusion Criteria:

Life expectancy < 3 months

Study Design

Enrollment

100000 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • association between major finding and outcome, Descriptive [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

Nathan Fowler

+1-617-658-4545nathan.fowler@bostongene.com

Locations

BostonGene

Recruiting

Waltham, Massachusetts, United States, 02453

Contacts

Krystle Nomie, PhD

617-658-4545krystle.nomie@bostongene.com

More Information

Sponsor

BostonGene

Last update posted

Feb 7, 2024

Last verified

Feb, 2024

Keywords

  • cancer
  • precision medicine
  • WES
  • RNA-seq
  • immuno-therapy
  • genomic
  • transcriptomic
  • multiomic

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by BostonGene on 2024-02-07.